A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 65
- 试验地点
- 1
- 主要终点
- 18F-AlF-NOTA-neurotensin PET/CT imaging of patients with Prostate Cancer
研究概览
简要总结
The aim of this study is to investigate the clinical value of [18F]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-neurotensin（18F-AlF-NOTA-neurotensin）positron emission tomography / computed tomography (PET/CT) in patients with prostate cancer (PCa).
详细描述
18F-AlF-NOTA-neurotensin is a radioligand targeting the neurotensinreceptor, which is widely expressed on the cell surface of PCa. The radioligand can be used for the diagnosis and stage of the PCa. A total of 5 volunteers and 60 PCa patients will be subjected to a 18F-AlF-NOTA-neurotensin PET/CT scan. The uptake of 18F-AlF-NOTA-neurotensin in organs and tumor lesions will be quantified as Standardized Uptake Values (SUVmax/SUVmean).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Histologically and/or clinically confirmed and/or suspicious of PCa.
- •Signed informed consent.
排除标准
- •Claustrophobia (unable to accept PET/CT scanning)
研究组 & 干预措施
18F-AlF-NOTA-neurotensin PET/CT
One injection of the radioligand 18F-AlF-NOTA-neurotensin Device: PET/CT Following injection of 18F-AlF-NOTA-neurotensin the participants will be subjected to whole body PET/CT
干预措施: 18F-AlF-NOTA-neurotensin (Drug)
结局指标
主要结局
18F-AlF-NOTA-neurotensin PET/CT imaging of patients with Prostate Cancer
时间窗: 12 months
The radioligand 18F-AlF-NOTA-neurotensin can be used to visualize prostate cancer
次要结局
- 18F-AlF-NOTA-neurotensin PET/CT prognostic factor for overall and disease specific survival(24 months)